Pharsight

Sunlenca patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9951043 GILEAD SCIENCES INC Therapeutic compounds
Feb, 2034

(9 years from now)

US10071985 GILEAD SCIENCES INC Therapeutic compounds
Aug, 2037

(13 years from now)

US11267799 GILEAD SCIENCES INC Solid forms of an HIV capsid inhibitor
Aug, 2038

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10654827 GILEAD SCIENCES INC Therapeutic compounds
Aug, 2037

(13 years from now)

Sunlenca is owned by Gilead Sciences Inc.

Sunlenca contains Lenacapavir Sodium.

Sunlenca has a total of 4 drug patents out of which 0 drug patents have expired.

Sunlenca was authorised for market use on 22 December, 2022.

Sunlenca is available in tablet;oral, solution;subcutaneous dosage forms.

Sunlenca can be used as in combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection.

Drug patent challenges can be filed against Sunlenca from 22 December, 2026.

The generics of Sunlenca are possible to be released after 16 August, 2038.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 22, 2027

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using LENACAPAVIR SODIUM ingredient

NCE-1 date:

22 December, 2026

Market Authorisation Date:

22 December, 2022

Treatment:

In combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection

Dosage:

TABLET;ORAL; SOLUTION;SUBCUTANEOUS

More Information on Dosage

SUNLENCA family patents

Family Patents